Merus N.V. is a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies known as Biclonics®. These bispecific antibody therapeutics are engineered to harness the immune system to target and eliminate cancer cells, offering more effective treatments with fewer side effects. The company operates in the biotechnology sector, primarily serving patients battling cancer. Merus collaborates with other life sciences companies, such as Caris Life Sciences, to enhance patient identification and enrollment for clinical trials, including the Zenocutuzumab Phase 1/2 eNRGy trial. The business model focuses on research and development, clinical trials, and partnerships to bring their therapeutic solutions to market. Revenue is generated through collaborations, licensing agreements, and potential future sales of approved therapies.

Keywords: oncology, bispecific antibodies, immune system, cancer treatment, clinical trials, biotechnology, Biclonics®, Zenocutuzumab, patient enrollment, therapeutic solutions.